{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000676","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.260085+00:00","generated_at":"2026-06-07T03:31:31.837579+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prime Medicine settles arbitration with Myeloid for $13.5M payment","bullets":["Company to pay Myeloid $13.5M to resolve two arbitration proceedings related to former research collaboration.","Settlement includes mutual covenants and release of all claims between parties.","Arbitrations previously disclosed in Q3 2023 Form 10-Q.","Agreement dated January 4, 2024, entered into between Prime Medicine and Myeloid."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000676","json":"https://secwatch.observer/filing/0001628280-24-000676.json","markdown":"https://secwatch.observer/filing/0001628280-24-000676.md","text":"https://secwatch.observer/filing/0001628280-24-000676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024000676/0001628280-24-000676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024000676/prme-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:31:31.837579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}